Prostate Cancer - Results from #180

Magnetic resonance imaging radiomic features for recurrent prostate cancer following proton radiation therapy-A pilot study. December 15, 2022

The Development of a Gleason Score-Related Gene Signature for Predicting the Prognosis of Prostate Cancer. December 15, 2022

Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group). December 15, 2022

Prospectively Accelerated T2-Weighted Imaging of the Prostate by Combining Compressed SENSE and Deep Learning in Patients with Histologically Proven Prostate Cancer. December 15, 2022

Women Play A Role in Prostate Health December 14, 2022

Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy. December 14, 2022

Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis. December 14, 2022

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival? December 14, 2022

Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short? December 14, 2022

Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling. December 14, 2022

Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. December 14, 2022

Novartis Receives European Commission Approval for Pluvicto® as the First Targeted Radioligand Therapy for Treatment of Progressive PSMA–positive Metastatic Castration-Resistant Prostate Cancer December 13, 2022

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer. December 13, 2022

The Impact of Exercise on Improving Body Composition and PSA in High-Risk Prostate Cancer Patients on Androgen-Deprivation Therapy. December 13, 2022

CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer. December 13, 2022

Assessment of the epidemiological trends for prostate cancer using administrative data in Ontario. December 13, 2022

When to order genomic tests: development and external validation of a model to predict high-risk prostate cancer at the genotypic level. December 13, 2022

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. December 13, 2022

PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry. December 13, 2022

European Health Union: Commission Welcomes Adoption of New EU Cancer Screening Recommendations December 12, 2022

Page 10 of 1275

email news signup